Literature DB >> 19650714

Cancer immunotherapy.

Constantin N Baxevanis1, Sonia A Perez, Michael Papamichail.   

Abstract

Recent scientific advances have expanded our understanding of the immune system and its response to malignant cells. The clinical goal of tumour immunotherapy is to provide either passive or active immunity against malignancies by harnessing the immune system to target tumours. Monoclonal antibodies, cytokines, cellular immunotherapy, and vaccines have increasingly become successful therapeutic agents for the treatment of solid and haematological cancers in preclinical models, clinical trials, and practice. In this article, we review recent advances in the immunotherapy of cancer, focusing on new strategies and future perspectives as well as on clinical trials attempting to enhance the efficacy of immunotherapeutic modalities and translate this knowledge into effective cancer therapies.

Entities:  

Mesh:

Year:  2009        PMID: 19650714     DOI: 10.1080/10408360902937809

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  25 in total

1.  Toll-like receptor agonist rMBP-NAP enhances antitumor cytokines production and CTL activity of peripheral blood mononuclear cells from patients with lung cancer.

Authors:  Cong Ding; Li Li; Yi Zhang; Zhenyu Ji; Chenglong Zhang; Taotao Liang; Xun Guo; Xin Liu; Qiaozhen Kang
Journal:  Oncol Lett       Date:  2018-07-20       Impact factor: 2.967

Review 2.  Clinically feasible approaches to potentiating cancer cell-based immunotherapies.

Authors:  V I Seledtsov; A G Goncharov; G V Seledtsova
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Pulmonary Toxicities of Immunotherapy.

Authors:  Mehmet Altan; Linda Zhong; Vickie R Shannon; Ajay Sheshadri
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  NK cell-based immunotherapy for malignant diseases.

Authors:  Min Cheng; Yongyan Chen; Weihua Xiao; Rui Sun; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2013-04-22       Impact factor: 11.530

5.  Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients.

Authors:  Pierpaolo Correale; Cirino Botta; Elodia Claudio Martino; Cristina Ulivieri; Giuseppe Battaglia; Tommaso Carfagno; Maria Grazia Rossetti; Antonella Fioravanti; Giacomo Maria Guidelli; Sara Cheleschi; Claudia Gandolfo; Francesco Carbone; Tatiana Cosima Baldari; Pierfrancesco Tassone; Pierosandro Tagliaferri; Luigi Pirtoli; Maria Grazia Cusi
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

Review 6.  Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide.

Authors:  Ann-Marie Chacko; Chunsheng Li; Daniel A Pryma; Steven Brem; George Coukos; Vladimir Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2013-06-11       Impact factor: 6.648

7.  Trends in cancer immunotherapy.

Authors:  Joseph F Murphy
Journal:  Clin Med Insights Oncol       Date:  2010-07-14

8.  Ganoderma Lucidum Polysaccharides Enhance the Abscopal Effect of Photothermal Therapy in Hepatoma-Bearing Mice Through Immunomodulatory, Anti-Proliferative, Pro-Apoptotic and Anti-Angiogenic.

Authors:  Qing-Hai Xia; Cui-Tao Lu; Meng-Qi Tong; Meng Yue; Rui Chen; De-Li Zhuge; Qing Yao; He-Lin Xu; Ying-Zheng Zhao
Journal:  Front Pharmacol       Date:  2021-07-06       Impact factor: 5.810

9.  Safety of in vitro amplified HLA-haploidentical donor immune cell infusions for childhood malignancies.

Authors:  Fei Zhang; Xiao-Fei Sun; Yong-Qiang Li; Zi-Jun Zhen; Hai-Xia Zheng; Jia Zhu; Qi-Jing Wang; Su-Ying Lu; Jia He; Juan Wang; Ke Pan; Rui-Qing Cai; Yan Chen; De-Sheng Weng; Fei-Fei Sun; Jian-Chuan Xia
Journal:  Chin J Cancer       Date:  2013-05-27

10.  Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1.

Authors:  Jérémie Ménager; Frédéric Ebstein; Romain Oger; Philippe Hulin; Steven Nedellec; Eric Duverger; Andrea Lehmann; Peter-Michael Kloetzel; Francine Jotereau; Yannick Guilloux
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.